Teladoc Health (NYSE:TDOC) Given New $10.00 Price Target at Canaccord Genuity Group

Teladoc Health (NYSE:TDOC) had its price target decreased by Canaccord Genuity Group from $12.00 to $10.00 in a research report released on Thursday,Benzinga reports. Canaccord Genuity Group currently has a buy rating on the health services provider’s stock.

Several other analysts have also recently weighed in on the company. Bank of America raised Teladoc Health from a “neutral” rating to a “buy” rating and set a $7.00 price target on the stock in a report on Thursday. Leerink Partners lowered their target price on shares of Teladoc Health from $8.50 to $5.50 and set a “market perform” rating on the stock in a research note on Thursday. Citigroup decreased their price target on shares of Teladoc Health from $10.00 to $9.00 and set a “neutral” rating on the stock in a report on Friday, January 9th. Piper Sandler restated an “overweight” rating and set a $9.00 price objective (down from $12.00) on shares of Teladoc Health in a research report on Thursday. Finally, BMO Capital Markets cut their target price on shares of Teladoc Health from $8.00 to $5.00 and set a “market perform” rating for the company in a research report on Thursday. Four analysts have rated the stock with a Buy rating, thirteen have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Teladoc Health has an average rating of “Hold” and an average price target of $7.80.

Teladoc Health Stock Performance

NYSE TDOC opened at $5.35 on Thursday. The company’s 50 day simple moving average is $6.03 and its two-hundred day simple moving average is $7.21. The company has a debt-to-equity ratio of 0.71, a current ratio of 2.70 and a quick ratio of 2.60. Teladoc Health has a 1 year low of $4.40 and a 1 year high of $10.02. The stock has a market capitalization of $949.46 million, a PE ratio of -4.69 and a beta of 2.12.

Teladoc Health (NYSE:TDOC) last released its quarterly earnings results on Wednesday, February 25th. The health services provider reported ($0.14) EPS for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.05. Teladoc Health had a negative net margin of 7.92% and a negative return on equity of 9.09%. The firm had revenue of $642.27 million during the quarter, compared to analyst estimates of $635.33 million. During the same period in the previous year, the business earned ($0.28) EPS. The business’s revenue for the quarter was up .3% on a year-over-year basis. Teladoc Health has set its Q1 2026 guidance at -0.450–0.350 EPS and its FY 2026 guidance at -1.100–0.700 EPS. Analysts predict that Teladoc Health will post -1.16 earnings per share for the current fiscal year.

Insider Activity

In other news, insider Fernando M. Rodrigues sold 4,209 shares of the company’s stock in a transaction dated Wednesday, December 3rd. The shares were sold at an average price of $7.48, for a total transaction of $31,483.32. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Charles Divita III sold 17,138 shares of the firm’s stock in a transaction dated Thursday, December 11th. The stock was sold at an average price of $7.63, for a total value of $130,762.94. Following the completion of the sale, the chief executive officer directly owned 201,036 shares in the company, valued at $1,533,904.68. The trade was a 7.86% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 33,288 shares of company stock worth $251,684 over the last ninety days. 0.58% of the stock is owned by insiders.

Hedge Funds Weigh In On Teladoc Health

A number of hedge funds and other institutional investors have recently made changes to their positions in TDOC. IFP Advisors Inc boosted its holdings in Teladoc Health by 412.1% in the third quarter. IFP Advisors Inc now owns 3,989 shares of the health services provider’s stock valued at $31,000 after acquiring an additional 3,210 shares in the last quarter. PNC Financial Services Group Inc. lifted its position in shares of Teladoc Health by 177.7% in the 4th quarter. PNC Financial Services Group Inc. now owns 4,391 shares of the health services provider’s stock worth $31,000 after purchasing an additional 2,810 shares during the period. Aster Capital Management DIFC Ltd boosted its stake in shares of Teladoc Health by 101.1% during the 3rd quarter. Aster Capital Management DIFC Ltd now owns 4,823 shares of the health services provider’s stock valued at $37,000 after purchasing an additional 2,425 shares in the last quarter. International Assets Investment Management LLC purchased a new position in shares of Teladoc Health during the fourth quarter valued at about $45,000. Finally, Bayforest Capital Ltd purchased a new position in shares of Teladoc Health during the third quarter valued at about $58,000. Institutional investors own 76.82% of the company’s stock.

Teladoc Health News Roundup

Here are the key news stories impacting Teladoc Health this week:

• Positive Sentiment: Q4 beat and narrower loss: Teladoc reported revenue of $642.3M (above estimates) and GAAP loss per share of $0.14 (better than consensus), driven by international growth and strength in Integrated Care; investors view the improved bottom line as a near-term positive. Teladoc Tops Q4 Earnings Estimates on International Growth & Lower Costs
• Positive Sentiment: Selective analyst support: Some firms are staying constructive (Bank of America upgraded to Buy, Piper Sandler reaffirmed Overweight, Canaccord remains a Buy despite lowering its PT), which bolsters demand from buyers who focus on recovery potential. Demystifying Teladoc Health: Insights From 8 Analyst Reviews
• Neutral Sentiment: Midterm growth roadmap: Management projects FY2026 revenue of roughly $2.47B–$2.59B and emphasized investments in AI, insurance relationships and international expansion — initiatives that support longer-term upside but will take time to materialize. Teladoc projects $2.47B–$2.59B revenue in 2026
• Negative Sentiment: Cautious forward guidance: Q1 2026 revenue guidance ($598M–$620M) and EPS guidance (-$0.45 to -$0.35) came in below Wall Street expectations, and FY EPS guidance (-$1.10 to -$0.70) is wider/weaker than consensus — a key reason for mixed investor reactions despite the quarter’s beat. Teladoc Health Reports Fourth Quarter and Full Year 2025 Results
• Negative Sentiment: Analyst price-target cuts: Several firms trimmed price targets (BMO, TD Cowen, Stifel, Wells Fargo, Leerink) and moved to Market Perform/Hold ratings in response to the softer outlook, adding selling pressure for investors focused on nearer-term valuation and earnings visibility. Analyst price-target updates

Teladoc Health Company Profile

Teladoc Health, Inc is a leading global provider of virtual healthcare services, offering on-demand medical consultations via phone, video, and mobile app platforms. The company connects patients with licensed physicians and specialists for non-emergency medical issues, mental health support, dermatology, and chronic condition management. By leveraging digital technologies and data analytics, Teladoc aims to enhance accessibility, reduce healthcare costs, and improve patient outcomes through personalized care plans and remote monitoring.

Teladoc’s service portfolio includes general medical visits, behavioral health sessions, expert medical services for complex cases, and wellness programs designed to support chronic disease management such as diabetes, hypertension, and heart disease.